Iuliana Shapira - Concepedia

Author

Iuliana Shapira

Also Known As

I SHAPIRA, I Shapira, I. E. Shapira, I. Shapira, Iuliana Shapira, Kyoung Sook Park, Shapira, Iuliana, Winer, Eric P., Yardley, Denise A.

100

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Hofstra University SUNY Downstate Health Sciences University Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute University of North Carolina at Chapel Hill

About

Iuliana Shapira is an author at Hofstra University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	669
2	Health Sciences	2	2	129
3	Cell Biology	2	2	119
4	Public Health	1	1	22
5	Health Policy	1	1	22

Iuliana Shapira

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Sara M. Tolaney, William T. Barry, Chau T. Dang, New England Journal of Medicine	2015	731
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Sara M. Tolaney, Hao Guo, Sònia Pernas, Journal of Clinical Oncology	2019	276
Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab Iuliana Shapira, Danieli Andrade, Steven L. Allen, Arthritis & Rheumatism	2012	195
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial Sara M. Tolaney, Paolo Tarantino, Noah Graham, The Lancet Oncology Breast OncologyOncologyBreast CancerAdjuvant PaclitaxelCancer Treatment	2023	151
Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity Chongmin Huan, Matthew L. Kelly, R. Steele, Nature Immunology Transcription Factors Tfe3Immunological MemoryAutoimmune DiseaseT-regulatory CellImmunology	2006	92
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial Myra F. Barginear, Richard J. Gralla, Thomas Bradley, Supportive Care in Cancer Fondaparinux SodiumThrombosisVenous ThrombosisCardiovascular DiseaseMedicine	2012	91
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer Chau T. Dang, Hao Guo, Julie Najita, JAMA Oncology	2015	91
Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology Jeffrey Peppercorn, Iuliana Shapira, Deborah Collyar, Journal of Clinical Oncology Biomedical EthicClinical EndpointPathologyClinical GuidelinesResearch Ethics	2010	76
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) Kathryn J. Ruddy, Hao Guo, William T. Barry, Breast Cancer Research and Treatment OncologyApt TrialClinical TrialsPharmacotherapyCancer Treatment	2015	75
Beliefs and attitudes towards participating in genetic research – a population based cross-sectional study Samantha M Kerath, Gila Klein, Marlena Kern, BMC Public Health	2013	74

Page 1